Leonhardt Ventures and Lionheart Health Secure Patent for Groundbreaking Bioelectric Stem Cell Technology
TL;DR
Exclusive rights to pioneering bioelectric stimulator patent gives Lionheart Health, Inc. and other startups a significant advantage in regenerative medicine.
The patent provides a method for using a bioelectric stimulator to control stem cell homing, proliferation, or differentiation and/or upregulate expression of specific proteins.
This breakthrough in organ regeneration research has the potential to make the world a better place by extending healthspan longevity and advancing medical innovations.
Leonhardt Ventures LLC's bioelectric stimulator patent represents a major breakthrough in regenerative medicine with potential for countless applications in health and wellness.
Found this article helpful?
Share it with your network and spread the knowledge!
Leonhardt Ventures LLC and its licensee Lionheart Health, Inc. have been granted a U.S. patent for a bioelectric stimulator that controls stem cell homing, proliferation, and differentiation. This technological breakthrough, covered by Patent 12,109,410, has far-reaching implications for regenerative medicine and organ regeneration.
The patented method involves using a bioelectric stimulator to target specific tissues, controlling stem cell behavior and upregulating the expression of key proteins involved in tissue growth and repair. These proteins include growth factors such as VEGF, IGF-1, and HGF, which play crucial roles in cellular regeneration and tissue healing.
This core technology is being applied to over 38 different medical applications, spanning areas such as cardiovascular health, brain health, major organ regeneration, medical aesthetics, and cancer treatment. The potential impact of this innovation on healthcare is substantial, offering new possibilities for treating a wide range of conditions and potentially extending healthspan longevity.
Lionheart Health, Inc. is already incorporating this technology into products and study protocols for skin and hair regeneration, body toning, sexual health, and joint health. Meanwhile, other Leonhardt Ventures spin-outs are applying the technology to specific medical challenges. For instance, BioLeonhardt and Valvublator, Inc. are focusing on heart and heart valve regeneration, while CerebraCell is exploring applications for stroke and traumatic brain injury recovery.
The patent's potential extends to major organ regeneration, with companies like PancreaCell, KidneyCell, and LiverCell working on applications for diabetes treatment and organ health. Additionally, CancerCell is investigating the technology's use in cancer treatment, highlighting the versatility of this bioelectric approach.
Dr. Jorge Genovese, VP of Bioelectric Research, emphasized the significance of this development, stating, "Being able to recruit stem cells where you want to when you want to in the body and then multiple them and control their differentiation is a major breakthrough in organ regeneration research."
As regenerative medicine continues to evolve, this patented bioelectric stimulation technology could play a pivotal role in advancing treatments for a multitude of health conditions. The ability to precisely control stem cell behavior in vivo opens up new avenues for personalized medicine and targeted therapies, potentially revolutionizing how we approach tissue repair and organ regeneration.
Curated from Newsworthy.ai
